Matches in Wikidata for { <http://www.wikidata.org/entity/Q65368156> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q65368156 description "clinical trial" @default.
- Q65368156 description "ensayu clínicu" @default.
- Q65368156 description "klinisch onderzoek" @default.
- Q65368156 description "клінічне випробування" @default.
- Q65368156 name "Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer" @default.
- Q65368156 name "Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer" @default.
- Q65368156 type Item @default.
- Q65368156 label "Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer" @default.
- Q65368156 label "Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer" @default.
- Q65368156 prefLabel "Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer" @default.
- Q65368156 prefLabel "Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer" @default.
- Q65368156 P1050 Q65368156-8B6719DF-C40E-45A8-84B8-DDBBA28A0AE6 @default.
- Q65368156 P1132 Q65368156-87A6CBA6-CA59-4391-B127-28B2B57A3E05 @default.
- Q65368156 P1476 Q65368156-58DE5115-6D58-46D1-B25D-30D30B021AFA @default.
- Q65368156 P17 Q65368156-05627CF6-80F6-447A-A275-75BEB83CE4A6 @default.
- Q65368156 P17 Q65368156-69139F69-D466-4AE1-B73B-BB879EBE823F @default.
- Q65368156 P17 Q65368156-7598CD58-013A-4AF3-B625-963138180BDD @default.
- Q65368156 P17 Q65368156-D3211F19-9036-4C75-8E1E-6107AEA772C8 @default.
- Q65368156 P17 Q65368156-D53D2935-493C-4647-A11E-33A378853EFD @default.
- Q65368156 P1813 Q65368156-78D83622-3AA6-4D59-9768-9CD7AC4C025F @default.
- Q65368156 P2899 Q65368156-A28491DE-C789-4303-BB1F-3C153A56C52C @default.
- Q65368156 P3098 Q65368156-B0159032-4C26-4E4C-8B43-2469DD03E043 @default.
- Q65368156 P31 Q65368156-26C4AABB-7584-4C55-9FAB-F60E3D1A0AE0 @default.
- Q65368156 P4844 Q65368156-420CE813-6FA1-4CA7-B15E-8B6B5BEB7EBB @default.
- Q65368156 P4844 Q65368156-8DF5A81B-B6D0-43C7-910D-57A6C1C9F19F @default.
- Q65368156 P4844 Q65368156-A41C6D0F-35C0-46A6-BBE1-E9967809064D @default.
- Q65368156 P4844 Q65368156-C98A2F5E-14C3-432B-AA03-DF73CD1AE73C @default.
- Q65368156 P4844 Q65368156-E3B18C19-030C-47F7-B2D9-8D290BC627C0 @default.
- Q65368156 P580 Q65368156-EF5B4A6B-C9E2-4DD2-A280-37D02CB452DC @default.
- Q65368156 P582 Q65368156-9A7AFEAC-E756-45EA-8076-7629D2D6CD60 @default.
- Q65368156 P6099 Q65368156-DD60F957-94EE-40C3-A35F-4D57B408E897 @default.
- Q65368156 P6153 Q65368156-650223DC-DEAD-4BDF-A19C-B0F7650587AF @default.
- Q65368156 P6153 Q65368156-A635B231-7C26-4B44-A433-0DA613DD705F @default.
- Q65368156 P6153 Q65368156-BBD8E84C-C237-48F5-A5FE-2F88A4A70C87 @default.
- Q65368156 P6153 Q65368156-DC4F2700-B980-4666-858E-919777E016AA @default.
- Q65368156 P6153 Q65368156-F8DBC027-4A5C-4F76-BC95-FE5B20729B59 @default.
- Q65368156 P8363 Q65368156-9F2E8EA4-9020-48C1-97F3-3C426B40E1C4 @default.
- Q65368156 P1050 Q5958765 @default.
- Q65368156 P1132 "+406" @default.
- Q65368156 P1476 "Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line" @default.
- Q65368156 P17 Q142 @default.
- Q65368156 P17 Q235 @default.
- Q65368156 P17 Q38 @default.
- Q65368156 P17 Q39 @default.
- Q65368156 P17 Q41 @default.
- Q65368156 P1813 "MITO16MANGO2b" @default.
- Q65368156 P2899 "+18" @default.
- Q65368156 P3098 "NCT01802749" @default.
- Q65368156 P31 Q30612 @default.
- Q65368156 P4844 Q18936 @default.
- Q65368156 P4844 Q29004943 @default.
- Q65368156 P4844 Q413299 @default.
- Q65368156 P4844 Q415588 @default.
- Q65368156 P4844 Q423762 @default.
- Q65368156 P580 "2013-11-01T00:00:00Z" @default.
- Q65368156 P582 "2017-12-01T00:00:00Z" @default.
- Q65368156 P6099 Q42824827 @default.
- Q65368156 P6153 Q2945711 @default.
- Q65368156 P6153 Q30280648 @default.
- Q65368156 P6153 Q30281556 @default.
- Q65368156 P6153 Q30282158 @default.
- Q65368156 P6153 Q3886628 @default.
- Q65368156 P8363 Q78089383 @default.